Welcome to Journal Watch. The content you requested requires sign in with a username and password.
More on Safety of Stopping MAC Prophylaxis
Results from a retrospective report of patients discontinuing secondary MAC prophylaxis lend support to recently updated guidelines suggesting that cessation of antimycobacterial therapy appears safe in antiretroviral-treated patients with a sustained increase in CD4-cell count to >100.
Sign In
Don't yet have a username or password?
Register now for
Journal Watch e-mail alerts and unlimited online
access to articles 6 months after publication.
Subscribe now for
Full, immediate online access to all Journal Watch content and services.
Already a subscriber? Activate your subscription to receive full online access.
Get full site access with a 7-day site pass for $19